HUE049013T2 - Farmakofór trail indukcióra - Google Patents

Farmakofór trail indukcióra

Info

Publication number
HUE049013T2
HUE049013T2 HUE15772254A HUE15772254A HUE049013T2 HU E049013 T2 HUE049013 T2 HU E049013T2 HU E15772254 A HUE15772254 A HU E15772254A HU E15772254 A HUE15772254 A HU E15772254A HU E049013 T2 HUE049013 T2 HU E049013T2
Authority
HU
Hungary
Prior art keywords
pharmacophore
trail induction
trail
induction
Prior art date
Application number
HUE15772254A
Other languages
English (en)
Inventor
Kim D Janda
Nicholas T Jacob
Jonathan W Lockner
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of HUE049013T2 publication Critical patent/HUE049013T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE15772254A 2014-03-31 2015-03-30 Farmakofór trail indukcióra HUE049013T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461972689P 2014-03-31 2014-03-31

Publications (1)

Publication Number Publication Date
HUE049013T2 true HUE049013T2 (hu) 2020-08-28

Family

ID=54241169

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15772254A HUE049013T2 (hu) 2014-03-31 2015-03-30 Farmakofór trail indukcióra

Country Status (18)

Country Link
US (4) US10239877B2 (hu)
EP (2) EP3662910A1 (hu)
JP (4) JP6756435B2 (hu)
KR (2) KR102611067B1 (hu)
CN (2) CN111499636B (hu)
AU (3) AU2015241069B2 (hu)
CA (2) CA3158795A1 (hu)
CY (1) CY1123093T1 (hu)
DK (1) DK3125898T3 (hu)
ES (1) ES2779979T3 (hu)
HR (1) HRP20200478T1 (hu)
HU (1) HUE049013T2 (hu)
LT (1) LT3125898T (hu)
PL (1) PL3125898T3 (hu)
PT (1) PT3125898T (hu)
RS (1) RS60163B1 (hu)
SI (1) SI3125898T1 (hu)
WO (1) WO2015153468A1 (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
EP2968294B1 (en) 2013-03-13 2019-05-01 Oncoceutics, Inc. 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on for use in the treatment of cancer
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
MX2016006318A (es) * 2013-11-15 2017-01-19 Oncoceutics Inc 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso.
EP3662910A1 (en) 2014-03-31 2020-06-10 The Scripps Research Institute Pharmacophore for trail induction
MD3250208T2 (ro) * 2015-01-30 2021-02-28 Oncoceutics Inc 7-Benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-onă și sărurile acesteia și utilizarea lor în terapie
CN104860948B (zh) * 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
SG10202108306UA (en) * 2016-01-29 2021-08-30 Oncoceutics Inc G protein-coupled receptor (gpcr) modulation by imipridones
AU2017310526B2 (en) 2016-08-12 2021-08-12 Edwin J. Iwanowicz Protein kinase regulators
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
GB2596010B (en) * 2019-02-11 2023-03-01 Madera Therapeutics Llc Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
WO2022029459A1 (en) 2020-08-06 2022-02-10 Eötvös Loránd Tudományegyetem Synthesis of novel imipridone derivatives and their evaluation for their anticancer activity
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN116751199A (zh) * 2023-06-02 2023-09-15 中国科学院基础医学与肿瘤研究所(筹) 一种线粒体蛋白酶靶向嵌合体、制备方法及用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE786028A (fr) * 1971-07-08 1973-01-08 Boehringer Sohn Ingelheim 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
JPS5374893A (en) 1976-12-15 1978-07-03 Fujitsu Ltd Driving method for semiconductor photosensitive device
JPS6132833U (ja) 1984-07-31 1986-02-27 日信工業株式会社 デイスクブレ−キ装置
EP2932968B1 (en) 2008-06-09 2018-01-17 Allergan, Inc. Compound for treating alpha adrenergic mediated conditions
JP2013525308A (ja) 2010-04-16 2013-06-20 キュリス，インコーポレイテッド Ｋ−ｒａｓ変異を有する癌の治療
WO2012078448A1 (en) * 2010-12-06 2012-06-14 Schering Corporation Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
CN103391945B (zh) * 2011-03-15 2016-11-09 奇斯药制品公司 异噁唑烷衍生物
US20140287931A1 (en) * 2011-04-04 2014-09-25 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
EP3679934B1 (en) 2011-04-29 2024-06-05 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
EP2968294B1 (en) * 2013-03-13 2019-05-01 Oncoceutics, Inc. 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on for use in the treatment of cancer
US9181237B2 (en) * 2013-10-04 2015-11-10 Mallinckrodt Llc Substituted berbines and their synthesis
EP3662910A1 (en) 2014-03-31 2020-06-10 The Scripps Research Institute Pharmacophore for trail induction

Also Published As

Publication number Publication date
HRP20200478T1 (hr) 2020-07-24
JP7186256B2 (ja) 2022-12-08
CA3158795A1 (en) 2015-10-08
CN106456643A (zh) 2017-02-22
JP6873201B2 (ja) 2021-05-19
EP3125898A4 (en) 2017-08-16
CY1123093T1 (el) 2021-10-29
AU2020286314A1 (en) 2021-01-21
ES2779979T3 (es) 2020-08-21
CN106456643B (zh) 2020-04-17
EP3125898B1 (en) 2019-12-25
LT3125898T (lt) 2020-04-10
KR20220163533A (ko) 2022-12-09
CN111499636A (zh) 2020-08-07
AU2015241069B2 (en) 2020-10-15
JP2020002170A (ja) 2020-01-09
PT3125898T (pt) 2020-04-01
KR20160138513A (ko) 2016-12-05
EP3662910A1 (en) 2020-06-10
CA2944452A1 (en) 2015-10-08
US10633385B2 (en) 2020-04-28
AU2015241069A1 (en) 2016-10-20
EP3125898A1 (en) 2017-02-08
US11891392B2 (en) 2024-02-06
CN111499636B (zh) 2023-01-13
DK3125898T3 (da) 2020-03-30
US20190284188A1 (en) 2019-09-19
JP6756435B2 (ja) 2020-09-16
SI3125898T1 (sl) 2020-07-31
KR102473930B1 (ko) 2022-12-05
JP2017511321A (ja) 2017-04-20
US10239877B2 (en) 2019-03-26
JP2021119157A (ja) 2021-08-12
US20200283440A1 (en) 2020-09-10
AU2022283729A1 (en) 2023-02-02
US20170107221A1 (en) 2017-04-20
WO2015153468A1 (en) 2015-10-08
CA2944452C (en) 2022-07-19
JP2023022184A (ja) 2023-02-14
RS60163B1 (sr) 2020-05-29
PL3125898T3 (pl) 2020-11-16
US20220002300A1 (en) 2022-01-06
KR102611067B1 (ko) 2023-12-06

Similar Documents

Publication Publication Date Title
GB2531928B (en) Image-stitching for dimensioning
GB201817189D0 (en) Image-stitching for dimensioning
HUE049656T2 (hu) 4-amino-imidazo-kinolin vegyületek
AP2017009836A0 (en) Aminopyridyloxypyrazole compounds
GB201415573D0 (en) Compounds
PL3125898T3 (pl) Farmakofor do indukcji trail
GB201411418D0 (en) Compounds
GB201410430D0 (en) Compounds
GB201402431D0 (en) Compounds
GB201417369D0 (en) Compounds
GB201416186D0 (en) Compounds
GB201404987D0 (en) Compounds
GB201417561D0 (en) Compounds
GB201406591D0 (en) Compounds
GB2524311B (en) Centraliser
GB201406956D0 (en) Compounds
AP2017009778A0 (en) Azetidinyloxyphenylpyrrolidine compounds
GB201412660D0 (en) Compounds
GB201417168D0 (en) Compounds
GB201407695D0 (en) Compounds
GB201403438D0 (en) Polymorphs
GB2525001B (en) Centraliser
GB201405361D0 (en) Compounds
GB201417829D0 (en) Compounds
GB201417832D0 (en) Compounds